Safety Profile

Abivax's Obefazimod shows promise in ulcerative colitis maintenance study

GSK's mRNA flu vaccine shows promise in phase II trial

IDEAYA Biosciences (NASDAQ:IDYA) shows strong phase 2 IDE397 results

AstraZeneca (NASDAQ:AZN) faces setback as Imfinzi trial misses goal

Taysha Gene Therapies (NASDAQ:TSHA) reports positive Rett Syndrome trial data

Pliant Therapeutics (NASDAQ:PLRX) unveils breakthrough IPF drug results

ACELYRIN (NASDAQ:SLRN) unveils breakthrough in TED therapy

Syntara (ASX:SNT) begins final cohort dosing in Phase 2 Myelofibrosis trial